Hepatitis C Testing and Treatment

Uses

Benefits

Risks & contraindications

Comparisons

Evidence quality

Highlighted claims

• Hepatitis C treatment completion rates in pharmacy-based programmes ranged from 49% to 86%. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff
• Community pharmacies detected 7.8% more hepatitis C cases compared with standard care in one study. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff
• None of the hepatitis C studies reported excluding participants because of active substance use. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff
• Pharmacy-led hepatitis C pathways effectively provided testing and treatment for people who use drugs, detected more cases than standard care, and demonstrated feasibility. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff
• Implementation barriers for pharmacy-based hepatitis C care included eligibility determination, reimbursement issues, restrictive legislation, and limited patient knowledge or documentation. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff
• Pharmacist-led hepatitis C care was the most expensive model in some comparisons but remained cost-effective. — Harm reduction and pharmacy practice: a scoping review of services for people who use drugs provided by pharmacy staff